You are here:

Novartis Pharmaceuticals UK Ltd

Name SMC ID No Status Sub. Type
 
aliskiren (Rasilez) 462/08 Not Recommended Non submission
aliskiren (Rasilez) 462/08 Not Recommended Full submission
aliskiren (Rasilez) 462/08 Not Recommended Resubmission
amlodipine besylate/valsartan (Exforge®) 350/07 Accepted Abbreviated Submission
canakinumab (Ilaris) 658/10 Not Recommended Non submission
canakinumab (Ilaris) 1210/16 Not Recommended Non submission
canakinumab (Ilaris) 882/13 Not Recommended Non submission
canakinumab (Ilaris) 1268/17 Not Recommended Non submission
canakinumab (Ilaris) Arthritis 883/13 Not Recommended Non submission
canakinumab (llaris) 926/13 Not Recommended Non submission
ceritinib (Zykadia) 1097/15 Accepted Full submission
ciprofloxacin 3mg/mL + dexamethasone 1mg/mL ear drops (Cilodex) 1256/17 Restricted Abbreviated Submission
daptomycin (Cubicin) 1141/16 Not Recommended Non submission
daptomycin (Cubicin) 449/08 Restricted Full submission
daptomycin 500 mg powder for intravenous infusion (Cubicin) 338/06 Restricted Abbreviated Submission
deferasirox (Exjade) 866/13 Not Recommended Non submission
deferasirox (Exjade) 347/07 Restricted Full submission
deferasirox (Exjade) 347/07 Restricted Resubmission
deferasirox (Exjade) 1246/17 Restricted Abbreviated Submission
dexrazoxane (Cardioxane) 419/07 419/07 Not Recommended Non submission
Diclofenac (Voltarol Gel Patch®) 199/05 Not Recommended Full submission
eltrombopag (Revolade) 1206/17 Restricted Abbreviated Submission
eltrombopag olamine (Revolade) 1164/16 Not Recommended Non submission
everolimus (Afinitor) 595/10 Not Recommended Full submission
everolimus (Afinitor) 872/13 Accepted Resubmission
everolimus (Afinitor) 872/13 Not Recommended Full submission
everolimus (Afinitor) 872/13 Not Recommended Resubmission
everolimus (Afinitor) 777/12 Superseded Full submission
everolimus (Afinitor) 1215/17 Superseded Full submission
everolimus (Afintor) 595/10 Accepted Resubmission
everolimus (Certican) 1117/15 Not Recommended Non submission
everolimus (Certican) 1288/17 Not Recommended Non submission
everolimus (Votubia) 787/12 Not Recommended Non submission
everolimus (Votubia) 884/13 Not Recommended Non submission
fingolimod (Gilenya) 763/12 Not Recommended Full submission
fingolimod (Gilenya) 763/12 Restricted Resubmission
fingolimod (Gilenya) 992/14 Restricted Full submission
fingolimod (Gilenya) 1038/15 Accepted Full submission
Fluvastatin (Lescol) 76/04 Restricted Full submission
glycopyrronium (Seebri Breezhaler) 829/12 Accepted Full submission
imatinib (Glivec) 584/09 Restricted Resubmission
imatinib (Glivec) 584/09 Restricted Resubmission
imatinib (Glivec) 584/09 Not Recommended Full submission
imatinib (Glivec) 923/13 Not Recommended Non submission
imatinib (Glivec) 426/07 Not Recommended Non submission
imatinib (Glivec) 427/07 Not Recommended Non submission
imatinib (Glivec) 428/07 Not Recommended Non submission
imatinib (Glivec) 429/07 Not Recommended Non submission
imatinib (Glivec) 430/07 Not Recommended Non submission
imatinib (Glivec) 01/02 Superseded Full submission
Imatinib (Glivec®) 08/02 Restricted Full submission
Imatinib (Glivec®) 26/02 Restricted Full submission
indacaterol (Onbrez Breezhaler) 619/10 Accepted Full submission
indacaterol maleate, glycopyrronium bromide (Ultibro Breezhaler) 922/13 Accepted Abbreviated Submission
Ketotifen hydrogen fumarate (Zaditen®) 65/03 Not Recommended Non submission
letrozole (Femara) 251/06 Restricted Full submission
Letrozole (Femara®) 152/05 Restricted Full submission
Lumiracoxib 100mg tablets (Prexige®) 245/06 Marketing Authorisation Withdrawn Full submission
Mycophenolate sodium (Myfortic®) 144/04 Accepted Full submission
nilotinib (Tasigna) 440/08 Superseded Full submission
nilotinib (Tasigna) 709/11 Superseded Full submission
Oestradiol (Estradot®) range of transdermal patches 117/04 Accepted Abbreviated Submission
ofatumumab (Arzerra) 1037/15 Restricted Full submission
ofatumumab (Arzerra) 1237/17 Not Recommended Non submission
omalizumab (Xolair) 611/10 Superseded Abbreviated Submission
omalizumab (Xolair) 1017/14 Restricted Full submission
Omalizumab 150mg powder and solvent for injection (Xolair) 259/06 Superseded Full submission
omalizumab 150mg powder and solvent for injection (Xolair) 259/06 Superseded Resubmission
omalizumab 150mg powder and solvent for injection (Xolair) 259/06 Superseded Resubmission
omalizumab 75mg, 150mg solution for injection (Xolair) 708/11 Superseded Abbreviated Submission
panobinostat (Farydak) 1122/16 Accepted Full submission
pasireotide (as pamoate) (Signifor) 1048/15 Accepted Full submission
pasireotide (as pamoate) (Signifor) 1311/18 Not Recommended Non submission
pasireotide (Signifor) 815/12 Not Recommended Non submission
pimecrolimus cream (Elidel®) 35/03 Not Recommended IRP
pimecrolimus cream (Elidel®) 35/03 Not Recommended Full submission
pimecrolimus cream (Elidel®) 35/03 Not Recommended Resubmission
ranibizumab (Lucentis) 711/11 Not Recommended Full submission
ranibizumab (Lucentis) 711/11 Restricted Resubmission
ranibizumab (Lucentis) 732/11 Restricted Full submission
ranibizumab (Lucentis) 732/11 Accepted Resubmission
ranibizumab (Lucentis) 907/13 Accepted Full submission
ranibizumab 10mg/ml solution for intravitreal injection (Lucentis) 381/07 Superseded Full submission
rivastigmine (Exelon) 310/06 Not Recommended Non submission
rivastigmine 4.6mg/24h and 9.5mg/24h transdermal Patch 414/07 Superseded Abbreviated Submission
ruxolitinib (Jakavi) 867/13 Not Recommended Non submission
ruxolitinib (Jakavi) 867/13 Accepted Full submission
ruxolitinib (Jakavi) 1166/16 Not Recommended Non submission
sacubitril/valsartan (Entresto) 1132/16 Accepted Full submission
secukinumab (Cosentyx) 1159/16 Accepted Full submission
secukinumab (Cosentyx) 1054/15 Restricted Full submission
secukinumab (Cosentyx) 1167/16 Superseded Full submission
telbivudine (Sebivo) 438/08 Accepted Full submission
tobramycin inhalation powder 28mg (TOBI Podhaler) 783/12 Superseded Full submission
trametinib (Mekinist) 1161/16 Restricted Full submission
trametinib 0.5mg, 2mg film-coated tablets (Mekinist) 1264/17 Not Recommended Non submission
valsartan (Diovan) 649/10 Restricted Abbreviated Submission
valsartan (Diovan) 351/07 Accepted Abbreviated Submission
Valsartan 40mg, 80mg and 160mg capsules and tablets (Diovan®) 162/05 Restricted Full submission
Valsartan/hydrochlorothiazide (Co-Diovan®) 121/04 Accepted Full submission

Back